Welcome to our dedicated page for Flora Growth SEC filings (Ticker: FLGC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Flora Growth Corp. (NASDAQ: FLGC) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as it transitions toward a rebrand as ZeroStack and emphasizes its role as a decentralized AI treasury company and global pharmaceutical distributor. These filings, drawn from the SEC’s EDGAR system, document Flora’s corporate actions, financing arrangements and governance decisions in detail.
Investors can review Form 8-K current reports describing material events such as the 1-for-39 share consolidation, the company’s regaining of compliance with Nasdaq’s minimum bid price requirement, and multiple private placement transactions involving common shares, pre-funded warrants, common share purchase warrants and convertible notes. Specific 8-K filings outline cash and token-based private placements, a convertible note with DeFi Development Corp., a convertible note arrangement with Zero Gravity Labs Inc., and the company’s plans to use proceeds and tokens to further its digital asset treasury strategy linked to $0G.
The page also includes proxy materials such as the DEF 14A definitive proxy statement for the 2025 Special Meeting of Shareholders. That document details proposals for the name change to ZeroStack Corp., the creation of a new class of preferred shares, amendments to the 2022 Incentive Compensation Plan, approvals for option grants, approvals related to private placement issuances, authority for a forward share split, and potential adjournments. Additional filings describe amendments to the 2022 Incentive Compensation Plan and the repricing and vesting changes for certain stock appreciation rights.
Through Stock Titan, these SEC filings are updated in real time from EDGAR and are paired with AI-powered summaries that highlight key terms, capital structure changes, and treasury strategy disclosures. Users can quickly understand how Flora structures its digital asset-related financings, how it manages its Nasdaq listing requirements, and how shareholder approvals shape its evolution into ZeroStack. Forms such as 10-K and 10-Q, when available, complement the 8-K and proxy materials by providing broader financial and operational context.
ZeroStack Corp., formerly Flora Growth Corp., has officially changed its corporate name and Nasdaq ticker. Effective January 29, 2026, the company’s name changed from “Flora Growth Corp.” to “ZeroStack Corp.” following previously approved Articles of Amendment under Ontario corporate law.
On the same date, the company’s common shares stopped trading on the Nasdaq Capital Market under the ticker symbol “FLGC” and began trading under the new symbol “ZSTK”. The common shares also received a new CUSIP number, 98956L101 (ISIN: CA98956L1013). Existing share certificates remain valid and do not need to be exchanged.
Flora Growth Corp. plans a primary offering of common shares under its shelf registration to raise cash. The company expects to use the proceeds to advance an AI-focused asset management strategy centered on cryptocurrency, particularly 0G tokens, and for working capital and general corporate purposes.
Flora, which will rebrand as ZeroStack Corp., now combines a digital asset treasury business with global pharmaceutical distribution through its German subsidiary Phatebo. It has exited its legacy hemp and cannabis operations and is positioning itself around decentralized AI infrastructure and international specialty drug distribution.
Flora Growth Corp. director reports no share ownership
Flora Growth Corp. director Laurence Zeifman filed an initial ownership report covering an event dated 01/06/2026. The Form 3 notes that he is a director of the company but states in the remarks section that no securities are beneficially owned. The filing also references an attached power of attorney (Exhibit 24.1), authorizing the execution of ownership reports on his behalf.
Flora Growth Corp. has filed a prospectus to register 966,497 common shares for potential resale by existing selling securityholders. These shares come from prior private transactions, including cash, token-based and note settlement deals, and may be sold from time to time on Nasdaq under the symbol FLGC. The company will not receive any proceeds from these resale transactions; all sale proceeds will go to the selling securityholders.
Flora, which plans to rebrand as ZeroStack, is shifting its strategy toward a digital asset treasury focused on 0G Tokens and other cryptocurrencies while also operating Phatebo, a German-based global pharmaceutical distributor. It has exited its legacy hemp and cannabis business and raised capital through cash and token private placements and convertible notes. As of January 2, 2026, Flora had 1,045,604 common shares outstanding.
Flora Growth Corp. reported board and committee changes. On January 6, 2026, the board unanimously appointed Larry Zeifman as a director, as a member of the audit, compensation, and nominating and corporate governance committees, and as Chair of the Audit Committee. The board also named Manfred Leventhal as Chair of the nominating and corporate governance committee.
The board determined that Mr. Zeifman is an independent director who meets Nasdaq and SEC standards for audit and compensation committee service. His appointment fills vacancies created by the passing of director Harold Wolkin on August 25, 2025. The company states there are no special arrangements, family relationships, or related-party transactions tied to Mr. Zeifman’s appointment, and no material compensation plan or award has been granted in connection with his joining the board.
Flora Growth Corp. filed a registration statement to register an additional 1,506,892 common shares under its 2022 Incentive Compensation Plan, as amended through December 19, 2025. These shares have not yet been issued and are of the same class as shares previously registered on earlier Form S-8 filings. The plan is intended to provide equity-based compensation to eligible participants of the company.
Flora Growth Corp. is registering 51,282 additional common shares for issuance under its 2022 Incentive Compensation Plan. These shares are reserved for future equity awards to employees, directors and other eligible participants, and none had been issued as of the filing date. The plan, which has been amended several times, uses the same class of common shares that Flora Growth previously registered on earlier Form S-8 filings, and this new statement incorporates those prior registrations by reference.
Flora Growth Corp. (FLGC) filed its Q3 2025 10‑Q, highlighting a strategic pivot to a digital‑asset treasury model tied to 0G tokens and a streamlined operating focus. Revenue was $9.7 million in Q3 and $26.3 million for the nine months. The company reported a Q3 net loss of $6.7 million and a year‑to‑date net loss of $9.8 million.
Cash was $13.1 million at September 30, 2025. Restricted digital assets totaled $55.3 million, primarily 21,766,135 0G tokens initially valued at $54.7 million received via a September PIPE, alongside $13.3 million in cash proceeds from that first closing. The company also sold its Cannabis Business on September 26, 2025 in exchange for cancellation of approximately $2.2 million in promissory notes, presenting these operations as discontinued.
FLGC executed a 1‑for‑39 reverse split and subsequently regained Nasdaq minimum bid compliance. Management states existing cash and digital assets are expected to cover working capital needs. Following governance changes after a director’s passing and leadership transitions tied to the cryptocurrency strategy, the board is working to restore required independent composition. As of October 30, 2025, shares outstanding were 741,261.
FAQ
What is the current stock price of Flora Growth (FLGC)?
What is the market cap of Flora Growth (FLGC)?
